New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:55 EDTISIS, ARWRArrowhead weakness related to Isis' competing HBV program, says Piper Jaffray
Arrowhead Research (ARWR) shares are lower after competitor ISIS Pharmaceuticals (ISIS) announced preclinical data on its antisense compound targeting hepatitis B virus. Piper anticipates Arrowhead will begin multi-dose ARC-520 Phase II studies in Q4 and reiterates its Overweight rating and $24 price target on Arrowhead.
News For ARWR;ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
16:09 EDTARWRNovartis reports 5.57% stake in Arrowhead
Subscribe for More Information
February 11, 2016
07:17 EDTISISLeerink to hold a conference
Subscribe for More Information
February 9, 2016
16:03 EDTARWRArrowhead reports Q1 EPS (32c), consensus (41c)
Reports Q1 revenue $43,750, consensus $130,000. Reports cash and equivalents $62.17M.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use